Histology and site of the indolent lymphoma that was concurrent with DLBCL
| DLBCL with concurrent: . | FL . | Others* . | MZL . | CLL/SLL . | LPL . | B-cell NHL NOS . |
|---|---|---|---|---|---|---|
| Composite pathology,† n (%) | 67 (61.5) | 8 (12.9) | 5 (33.3) | — | 1 (50.0) | 2 (6.5) |
| Discordant pathology,†n (%) | 25 (22.9) | 50 (80.6) | 9 (60.0) | 11 (78.6) | 1 (50.0) | 29 (93.5) |
| Discordant in tissue | 11 | 2 | 1 | — | 1 | — |
| Discordant in bone marrow | 11 | 48 | 8 | 11 | — | 29 |
| Discordant in both tissue and bone marrow | 3 | — | — | — | — | — |
| Both composite and discordant pathology, n (%) | 17 (15.6) | 4 (6.5) | 1 (6.7) | 3 (21.4) | — | — |
| Discordant in tissue | 2 | — | — | — | — | — |
| Discordant in bone marrow | 14 | 4 | 1 | 3 | — | — |
| Discordant in both tissue and bone marrow | 1 | — | — | — | — | — |
| Total, n | 109 | 62 | 15 | 14 | 2 | 31 |
| DLBCL with concurrent: . | FL . | Others* . | MZL . | CLL/SLL . | LPL . | B-cell NHL NOS . |
|---|---|---|---|---|---|---|
| Composite pathology,† n (%) | 67 (61.5) | 8 (12.9) | 5 (33.3) | — | 1 (50.0) | 2 (6.5) |
| Discordant pathology,†n (%) | 25 (22.9) | 50 (80.6) | 9 (60.0) | 11 (78.6) | 1 (50.0) | 29 (93.5) |
| Discordant in tissue | 11 | 2 | 1 | — | 1 | — |
| Discordant in bone marrow | 11 | 48 | 8 | 11 | — | 29 |
| Discordant in both tissue and bone marrow | 3 | — | — | — | — | — |
| Both composite and discordant pathology, n (%) | 17 (15.6) | 4 (6.5) | 1 (6.7) | 3 (21.4) | — | — |
| Discordant in tissue | 2 | — | — | — | — | — |
| Discordant in bone marrow | 14 | 4 | 1 | 3 | — | — |
| Discordant in both tissue and bone marrow | 1 | — | — | — | — | — |
| Total, n | 109 | 62 | 15 | 14 | 2 | 31 |
—, no case; NOS, not otherwise specified.
All other indolent lymphomas other than FL, including MZL, CLL/SLL, LPL, and B-cell NHL NOS (listed in separate columns as well).
Composite histology means DLBCL and the indolent component were at the same site and discordant histology means DLBCL and the indolent component were at different sites.